Ministry of Strategic Industries presents FP-1 long-range drone flying up to 1600 km
Source: Mezha, a technology and IT news platform within Ukrainska Pravda's holding company
Details: Information displayed at the stand indicates that the FP-1 drone is designed to strike enemy targets at strategic depth. It can carry a warhead of up to 120 kilograms and has a range of up to 1,600 kilometres. The weight of the warhead likely affects the maximum flight distance.
Long-range FP-1 drone
"This drone is already being produced in very large volumes, and there is considerable interest from partners. This product was developed in Ukraine and scaled up very quickly. This is another thing we can share with our partners," said Anna Hvozdiar, Deputy Minister of Strategic Industries.
Background: President Zelensky ordered the production of 30,000 long-range drones by 2025 last year. Oboronka reports that the contracting process started in autumn 2024.
Support Ukrainska Pravda on Patreon!
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Jensen Huang Has Been Unloading Nvidia Stock This Year. Should Investors Be Worried?
Key Points Jensen Huang revealed his plan to sell up to 6 million shares of Nvidia months ago. Even after his recent stock sales, he still owns around 858 million shares of the chipmaker. The stock is trading at all-time highs and commands a significant premium. 10 stocks we like better than Nvidia › Investors oftentimes view insider selling as a sign that a stock may be in trouble, or perhaps as a hint that insiders don't see more room for it to rise. That can potentially raise red flags for a stock, especially when a CEO is involved. Nvidia (NASDAQ: NVDA) has been a top-performing stock for years, and the company is now the most valuable in the world. But its CEO, Jensen Huang, has been unloading shares of the business recently. This month, he has sold hundreds of thousands of shares, and that won't be the end of the selling. What's behind his moves, and should retail investors also consider cashing out in light of them? Huang's stock sales are minimal in relation to his overall position in Nvidia Although Nvidia's CEO has been selling shares this year, there are a couple of reasons investors shouldn't be spooked. The first is that his stock sales are part of a pre-published plan that he made known to the public. In March, Huang submitted a Rule 10b5-1 plan to sell up to 6 million shares. Once such plans are put in motion, they are executed by a designated broker who makes the trades at preset times. That ensures that the sales aren't being influenced by new insider information the executive might have. It's not uncommon for executives to periodically unload some of their shares over time, especially when they hold a lot of stock in a company. And it certainly doesn't mean that they are expecting their stock to struggle. Secondly, even after all of those 6 million shares are sold, Huang will still have a considerable position in the company. He now owns around 858 million shares -- around 3.5% of Nvidia's outstanding shares. He remains its top individual shareholder by far, and only a few institutions hold more of its shares than he does. So while these stock sales may seem significant, in the context of his overall position, they are not drastic by any stretch. Nvidia's stock has been rising and is trading at an elevated premium Huang's stock sale isn't a reason to be concerned about the business. Demand for Nvidia's artificial intelligence (AI) chips remains strong, and there's little reason to be worried about that growth slowing down just yet. Analysts at Grand View Research project that the AI chipset market will grow at a compound annual rate of 28.9% through the end of the decade, and Nvidia should be a huge beneficiary of that. But investors should still consider valuation. Right now, Nvidia is trading at 55 times its trailing earnings, which is a fairly high multiple given that the average ratio for the S&P 500 is less than 25. Although its growth prospects are high, investors shouldn't assume that Nvidia's dominance in the AI chip market will remain uncontested, as some tech giants are designing their own custom AI chips. And given that it trades at such a high premium, expectations will be high for the business. Effectively, there's a lot of future hoped-for growth already priced into Nvidia's stock, which may limit the returns of investors who buy right now. Should you buy Nvidia's stock today? Nvidia is trading at all-time highs, and its market cap of $4.2 trillion makes it the most valuable company in the world. While there's a lot of room for the tech stock to go higher as it profits from its domination of the AI chip market, there is also no margin of safety for investors if, for example, there is a slowdown in the economy and companies pull back on AI-related spending. Investors may want to consider mirroring Huang's recent stock sale and cash out some shares right now while still maintaining a position in the company. Nvidia is a market leader, and even if you don't expect it to double or triple in value again in the short term, it still has the potential to deliver market-beating returns. A buy-and-hold position may still make a lot of sense for growth investors, but if you're holding onto Nvidia stock today, you may also want to consider selling a fraction of your position and booking some profits. Should you buy stock in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,083,392!* Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Jensen Huang Has Been Unloading Nvidia Stock This Year. Should Investors Be Worried? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Wegovy maker Novo's profit warning triggers $70 billion share rout
By Jacob Gronholt-Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market. Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started. Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously. Its shares plunged nearly 30% before paring some losses to trade down over 20% by mid-afternoon. The shares are now down 44% this year. "The magnitude of the guidance cut is a shocker," Markus Manns, a portfolio manager at mutual fund firm Union Investment, a Novo shareholder, told Reuters, adding that Novo's issues went deeper than "compounded" copycats to Wegovy. Compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs. Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. U.S. law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or formulations. The company said in a statement that it cut its 2025 sales outlook due to lower growth expectations in the second half in the U.S., both for Wegovy and Ozempic in the GLP-1 diabetes market. The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen. At its peak in June 2024, Novo was worth as much as $615 billion, but its shares have plunged on investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the U.S. market. "The stock has gone from being a market darling to one of its biggest letdowns," said Angelo Meda, portfolio manager and head of equities at Banor SIM in Milan, which has a small Novo stake. "The biggest concern is the illegal channel siphoning away market share - something that's hard to quantify. Rebuilding trust will take time." NEW CEO AN INSIDER Doustdar, an Iranian-born, Austrian national, who grew up in the United States, joined Novo in 1992 and will take on the new role on August 7. He currently serves as vice president for international operations, a role he took after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said. "We need to increase the sense of urgency and execute differently," Doustdar told investors and analysts on a call. "The fact that my announcement comes right after the guidance update, just makes the mandate ahead even more clear." Some analysts and investors had argued that Novo should select an American, or a person with extensive experience working in the United States as its next CEO. Novo has lost its first-mover advantage in the United States this year to U.S. rival Eli Lilly. The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the United States, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. In May, Novo said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22. "Unfortunately, our latest market research indicates that has not happened," Chief Financial Officer Karsten Munk Knudsen said on a call with analysts on Tuesday. One million or more U.S. patients are still using compounded GLP-1s, he said. Novo has stepped up its dialogue with the U.S. FDA to limit unlawful compounding of its drugs, the head of U.S. operations David Moore added on the call. "Compounding continues to be an issue that we have to address," Moore said. ($1 = 0.8672 euros) Sign in to access your portfolio
Axios
4 hours ago
- Axios
Trump's tax bill blows $1.2B hole in Colorado budget
President Trump's "big, beautiful bill" will create a $1.2 billion hole in Colorado's current state budget, according to a new pair of economic forecasts. Why it matters: The financial hit is unprecedented and forces lawmakers to consider raising taxes or cutting key services. "We don't have the money to pay our bills, so we need to do something," Mark Ferrandino, the governor's budget director, told top lawmakers in a presentation Wednesday. State of play: Unlike most states, Colorado's tax policies are intricately linked to federal law, making the state more susceptible to changes made by Congress compared to peers. By the numbers: The federal spending bill, also known as H.R. 1, will lower the state's individual income tax collections by $376 million and reduce corporate taxes by $825 million in the current fiscal year, the governor's office estimated. Other federal tax changes, such as no tax on tips and interest on car loans, will cost millions more in lost revenue, legislative analysts noted. What's next: To address the deficit in the $44 billion budget, Colorado lawmakers are preparing to return to the state Capitol for a special legislative session as early as mid-August. The options to address the budget hole include tapping into the state's reserve fund, cutting back on safety net programs such as Medicaid and raising taxes and fees. What they're saying:"We have difficult decisions ahead and will do everything we can to minimize the harm, but there's no avoiding the fact that these cuts will hurt Colorado families," Senate President James Coleman (D-Denver) said in a statement. The other side: Republicans called the legislative hearing "political theatrics" and blamed the Democratic majority's overspending in prior years for the current budget crisis.
